发明授权
US08470335B2 Recombinant SARS-CoV nsp12 and the use of thereof and the method for producing it
有权
重组SARS-CoV nsp12及其用途及其制备方法
- 专利标题： Recombinant SARS-CoV nsp12 and the use of thereof and the method for producing it
- 专利标题（中）： 重组SARS-CoV nsp12及其用途及其制备方法
-
申请号： US12997816申请日： 2008-06-13
-
公开(公告)号： US08470335B2公开(公告)日： 2013-06-25
- 发明人: Jong Won Oh , Dae Gyun Ahn
- 申请人： Jong Won Oh , Dae Gyun Ahn
- 申请人地址： KR Seoul
- 专利权人： Industry-Academic Cooperation Foundation, Yonsei University Kookmin University Industry Academy Cooperation Foundation
- 当前专利权人： Industry-Academic Cooperation Foundation, Yonsei University Kookmin University Industry Academy Cooperation Foundation
- 当前专利权人地址： KR Seoul
- 代理机构： Swanson & Bratschun, LLC
- 国际申请： PCT/KR2008/003333 WO 20080613
- 国际公布： WO2009/151165 WO 20091217
- 主分类号： C12N15/50
- IPC分类号： C12N15/50 ; C12N15/33 ; C07K16/00 ; C07K16/10 ; A61K39/00 ; A61K39/12 ; A61K39/215 ; C12P21/06 ; C12Q1/70
摘要：
The present invention relates to a recombinant severe acute respiratory syndrome coronavirus (SARS-CoV) non-structural protein (nsp) 12 with an RNA polymerase activity, its expression vector, its preparation method, and its use. According to the present invention, a soluble recombinant SARS-CoV nsp12 with an RdRp activity of initiating SARS-CoV genome synthesis can be over-expressed in the transformed host cells, and conveniently purified with high purity. An in vitro replication system important for studying SARS-CoV replication can be established with the purified recombinant SARS-CoV nsp12. SARS-CoV nsp12 produced by the present invention can also be used as a target for the development of anti-viral agents against SARS-CoV. In addition, materials inhibiting RNA-dependent RNA polymerase (RdRp) activity of nsp12 can be screened efficiently according to the present invention as the optimal conditions for the RdRp assay with SARS-CoV nsp12 were found.
公开/授权文献
信息查询
IPC分类:
